Click here to print this page

Planning Retirement Online

Cancer wonder drug not available on NHS

If you read this week’s Daily Mail, you will have seen the story that NICE (Britain’s National Institute for Health and Care Excellence) has announced that the new cancer wonder drug Nivolumab is too expensive and so won’t be available in England and Wales.

Nivolumab has shown to be twice as effective as chemotherapy with far fewer side effects.

To be told you have a life threatening disease is of course totally devastating. But to then be told there is a drug that could help or even stop it progressing, but you can’t have it because Britain can’t afford the cost must be even more shattering.

But here at Laterlife we remembered a breaking story just last July when it was announced that Nivolumab had been approved for lung cancer through the UK’s early access to medicine’s scheme and had been given an EU license for melanoma.

So does this mean that some patients can still have access to this breakthrough treatment.

Laterlife decided to find out the facts and contacted NICE.

They told Laterlife:

“Our independent advisory committee recognised that Nivolumab is a promising new treatment. However, even allowing for the extra flexibility they have for making recommendations about new cancer treatments, it could not be considered a cost effective use of NHS resources.”

However, NICE  has also told us that they are today (Dec 16th) opening a consultation on  preliminary draft guidance on Nivolumab (marketed as Opdivo by Bristol-Myers Squibb) to treat a specific type of lung cancer known as squamous cell, which is advanced or has spread to other areas of the body in adults whose disease has progressed after chemotherapy.

They said:

“Consultees, including the manufacturer, healthcare professionals and members of the public are now able to comment on the preliminary guidance. Comments received during this consultation will be fully considered by the Committee and following this meeting the next draft guidance will be issued.

“Until final guidance is issued, NHS bodies should make decisions locally on the funding of specific treatments. Once NICE issues its final guidance on a technology, it replaces local recommendations across the country.

 

Back to LaterLife Interest Index


Bookmark This Share on Facebook Receive more like this

 

Latest Articles:

Health food of the month: Pumpkins

pumpkins

Pumpkins might be popular for Halloween, but they are also a great addition to everyday diets.

more

Top tips to achieve a back-friendly car

Back problems can be triggered by poor posture and drivers are particularly at risk. By adjusting and setting up your car seat properly, your posture can be improved and the risk of back pain minimised.

more

Are you fit to drive?

Woman driving in car

We need to consider our own driving as we get older, but also that of any elderly relatives. Ensuring medically fitness to drive is a responsibility everyone should take seriously whatever their age.

more

Cellulitis is an infection that needs immediate treatment

Woman in bed

Many people believe cellulitis is something to do with weight and obesity but in fact cellulitis is a potentially dangerous infection.

more

Back to LaterLife Health Section

Visit our Pre-retirement Courses section here on laterlife or our dedicated Retirement Courses site

Bookmark


Advertise on laterlife.com



LaterLife Travel Insurance in Association with Avanti